Abstract: Objective To explore the efficacy and toxic reaction of concurrent chemoradiotherapy for recurrent cervical cancer.Methods Form October 2003 to November 2006, 41 recurrent cervical cancer patients were treated by 3DCRT of 50-65Gy.Chemotherapy was given concurrently using capecitabine(1500mg/m²orally, d1-d14, 21 days per cycle)and nedaplatin(60mg/m²iv drop, d1, 21 days per cycle).The concurrent chemotherapy was used 2 circles.After CCRT, 2-4 circles of the same program for consolidation chemotherapy were used one month later.Results All of the patients had finished the CCRT, in which 33 patients were given consolidation chemotherapy for 4 cycles, 3 patients were given 3 cycles and 5 patients were given 2 cycles.The total response, complete response rate and partial response rate were 78%, 26.8%(11/41)and 51.2%(21/41), respectively.The medium overall survival was 24.8 months.The 1-and 2-year survival rates were 58.5%and 31.7% respectively.The pain-alleviation rate and the mean pain-alleviation time were 90.3% and 7.8 months respectively.The hemorrhage control rate was 90.9%(10/11).Quality of life was improved without any treatment related death.Conclusions Capecitabine and cisplatin combined with concurrent radiotherapy for recurrent cervical cancer is effective and well-tolerated in patients with post-operatively local regionally recurrent or advanced cervical cancer.